Citius Pharmaceuticals (CTXR) News Today $1.84 -0.02 (-0.81%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period D. Boral Capital Reiterates "Buy" Rating for Citius Pharmaceuticals (NASDAQ:CTXR)February 20 at 2:05 AM | americanbankingnews.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals (CTXR) to Release Quarterly Earnings on WednesdayFebruary 11, 2025 | americanbankingnews.comCitius Pharmaceuticals and Citius Oncology announce J-Code issued for LymphirFebruary 6, 2025 | markets.businessinsider.comCitius Pharma's LYMPHIR gains permanent J-code for billingFebruary 6, 2025 | msn.comCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesFebruary 6, 2025 | prnewswire.comCitius Pharmaceuticals announces $3M registered direct offering priced ATMJanuary 8, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanuary 8, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025January 7, 2025 | prnewswire.comCitius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesJanuary 6, 2025 | prnewswire.comD. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)December 30, 2024 | msn.comCitius Pharmaceuticals upgraded to Buy from Hold at D. Boral CapitalDecember 30, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides ...December 28, 2024 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateDecember 27, 2024 | prnewswire.comCitius Pharma Held Productive FDA Meeting To Discuss Phase 3 Mino-Lok Program, Pathway To ApprovalNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-LokNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNovember 25, 2024 | prnewswire.comD. Boral Capital Downgrades Citius Pharmaceuticals (CTXR)November 23, 2024 | msn.comCitius Pharmaceuticals downgraded to Hold from Buy at D. Boral CapitalNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals announces 1-for-25 reverse stock splitNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNovember 22, 2024 | prnewswire.comCitius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingNovember 18, 2024 | prnewswire.comCitius Pharmaceuticals Announces $3 Million Registered Direct OfferingNovember 15, 2024 | prnewswire.comEquities Analysts Issue Forecasts for CTXR FY2024 EarningsCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Citius Pharmaceuticals in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now expectsNovember 14, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CTXR Q1 Earnings?Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino anticipates that thNovember 13, 2024 | marketbeat.comBuy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial OutlookNovember 13, 2024 | markets.businessinsider.comCitius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy RatingNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Citius Pharmaceuticals (NASDAQ:CTXR)HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday.November 12, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid TumorsNovember 11, 2024 | prnewswire.comCitius Pharma (NASDAQ:CTXR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short InterestCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 12,530,000 shares, a decrease of 6.4% from the August 31st total of 13,390,000 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover ratio is presently 5.8 days.September 30, 2024 | marketbeat.comArmistice Capital LLC Acquires Shares of 10,156,000 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)Armistice Capital LLC acquired a new position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,156,000 shares of the company's stSeptember 26, 2024 | marketbeat.comCitius Pharmaceuticals defers FDA milestone paymentSeptember 15, 2024 | uk.investing.comCitius Pharmaceuticals faces potential Nasdaq delistingSeptember 14, 2024 | uk.investing.comCitius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologySeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short InterestCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) was the recipient of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 12,280,000 shares, a drop of 16.1% from the July 31st total of 14,630,000 shares. Based on an average daily volume of 2,250,000 shares, the days-to-cover ratio is presently 5.5 days.September 3, 2024 | marketbeat.comCTXR Oct 2024 2.000 callAugust 21, 2024 | ca.finance.yahoo.comBuy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product DataAugust 17, 2024 | markets.businessinsider.comTenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market UpdateAugust 13, 2024 | finanznachrichten.deCitius Pharmaceuticals (NASDAQ:CTXR) Releases Earnings Results, Misses Estimates By $0.01 EPSCitius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01).August 13, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | prnewswire.comCitius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.August 12, 2024 | prnewswire.comCitius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming DevelopmentsAugust 12, 2024 | prnewswire.comCitius wins FDA nod for Lymphir in cutaneous T-cell lymphomaAugust 9, 2024 | msn.comUS FDA approves Citius' blood cancer therapyAugust 8, 2024 | reuters.comCitius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaAugust 8, 2024 | prnewswire.comStock Traders Purchase High Volume of Call Options on Citius Pharmaceuticals (NASDAQ:CTXR)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders acquired 6,590 call options on the company. This is an increase of 1,308% compared to the average daily volume of 468 call options.August 6, 2024 | marketbeat.comCitius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.August 5, 2024 | prnewswire.comWhen Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?July 22, 2024 | finance.yahoo.com Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼-0.750.60▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼41▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JSPR News Today ANRO News Today SKYE News Today DBVT News Today IMUX News Today CTOR News Today GALT News Today INZY News Today ABOS News Today ENTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
